View PowerPoint Presentation - Vision Research Coordinating Center

More documents

Recommendations

Info

POAG Endpoints by Central Corneal Thicknessand Baseline Vertical C/D Ratio in Observation Group*Vertical C/D Ratio>0.5022% 16% 8%>0.30 to 555 to < 588 >588Central Corneal Thickness (microns)June, 2002* through 8 Nov 2001
60-year-old WF IOP 24 / 24 C/D ratio 0.1 vertical Corneal thickness 600 μ Risk of POAG ~ 1% / 5 yearsJune, 2002
Page 1 and 2: The Ocular HypertensionTreatment St
Page 3 and 4: Why did we do this study?Don’t we
Page 5 and 6: Ocular Hypertension Treatment Study
Page 7 and 8: Patient found eligible for OHTS•
Page 9 and 10: Baseline Characteristics by Randomi
Page 15 and 16: IOP By RaceMedicationObservationAfr
Page 17 and 18: Progress and Outcome of Study Parti
Page 19 and 20: Proportion POAG1 st Visual Field PO
Page 21 and 22: First POAG Endpoint per Participant
Page 23 and 24: Treatment perhaps less protectivein
Page 25 and 26: Percent Reporting Changes inIris, L
Page 27 and 28: Borderline Safety DifferencesBetwee
Page 29 and 30: Significant Baseline Predictive Fac
Page 31 and 32: Significant Baseline Predictive Fac
Page 33: POAG Endpoints by Central Corneal T
Page 37 and 38: 60-year-old WF IOP 28 / 28 C/D rati
Page 39 and 40: 72-year-old BM IOP 25 / 25 C/D rati
Page 41 and 42: Weaknesses1. Convenience sample rat
Page 43 and 44: Possible Misinterpretations of OHTS
Page 45: OHTS Clinical CentersBascom Palmer

View PowerPoint Presentation - Vision Research Coordinating Center

Create successful ePaper yourself

Delete template?

Save as template?